米非司酮为抗孕酮和抗糖皮质激素甾体类药物,有副作用少、患者痛苦小等特点。米非司酮在临床上不仅能够干扰子宫膜和蜕膜靶器官水平的孕酮,终止早、中、晚期妊娠,用于死胎引产和避孕。还能有效治疗子宫肌瘤、子宫腺肌症以及异位妊娠等常见疾病。由于米非司酮在体内外都具有较强的抗孕激素和抗糖皮质激素的作用,目前在临床上应用最为成熟的是终止49d内早孕,已通过国家食品药品监督管理总局的正式批准[1]。为了让米非司酮在妊娠终止临床应用方面有更多的了解,笔者对其 Mifepristone is an anti-progesterone and anti-glucocorticoid steroid, with fewer side effects and less pain in patients. Mifepristone clinically not only can interfere with uterine membrane and decidual target organ level of progesterone, termination of early, middle and late pregnancy, for stillbirth induction and contraception. Can effectively treat uterine fibroids, adenomyosis and ectopic pregnancy and other common diseases. Because mifepristone in vivo and in vitro have a strong anti-progesterone and anti-glucocorticoid effect, the most mature clinical application is the termination of early pregnancy within 49d, has been approved by the State Food and Drug Administration [ 1]. In order to make mifepristone terminate the clinical application of pregnancy have more understanding, I author it